Tactile Systems Technology, Inc. TCMD R2K
Healthcare · Medical Devices · United States
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
READ MORE ›$24.61
+149.09% 1Y
Market & Price
Market Cap
$555.11M
Current Price
$24.61
High / Low (52W)
$33.05 / $9.52
Beta
0.82
Valuation
Stock P/E
28.29
Industry PE
23.65
Forward P/E
16.35
PEG Ratio
17.79
Book Value
$9.59
Price to Book
2.57
P/S
1.62
EV/EBITDA
12.75
Dividend Yield
-
Profitability & Returns
ROCE
13.90%
ROE
9.59%
ROA
7.31%
Profit Margin
5.91%
Op Margin
-2.04%
EPS (Latest Qtr)
$-0.08
EPS (TTM)
$0.87
Balance Sheet & Liquidity
Debt/Equity
0.07
Quick Ratio
3.57
Current Ratio
4.24
Debt
$15.17M
Total Assets
$273.94M
Current Assets
$165.17M
Working Capital
$124.21M
Ownership
Promoter Holding
2.31%
Chg in Prom Hold
-
FII / Inst Holding
103.27%
Chg in FII Hold
0.02%
Financial Snapshot
Enterprise Value
$495.29M
Total Revenue (TTM)
$343.52M
EBITDA
$38.84M
Free Cash Flow
$33.46M
Operating Cash Flow
$42.05M
Shares Outstanding
22.56M
Gross Margin
76.39%
Payout Ratio
0.00%
Growth (CAGR)
Revenue 5Y
10.12%
Profit 5Y
68.94%
Revenue (YoY)
22.80%
Earnings (YoY)
-
PROS
- Compounding revenue at 10.1% over 5 years.
- Profit CAGR of 68.9% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 25.5% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TCMD Tactile Systems Technology, Inc. R2K | 24.61 | 28.29 | $555.11M | - | 13.90% | 9.59% | 10.12% | 68.94% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Ad space
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 19.85M | 26.26M | 28.28M | 34.89M | 26.85M | 34.13M | 36.32M | 46.45M | 37.62M | 45.20M | 49.61M | 57.06M | 43.67M | 35.12M | 49.09M | 59.24M | 42.77M | 51.06M | 52.50M | 47.98M | 59.65M | 65.26M | 58.85M | 68.34M | 69.59M | 61.09M | 73.22M | - | - | 61.27M | 78.91M | 85.75M | 103.59M | 75.27M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 15.92M | 20.11M | 20.75M | 22.59M | 17.65M |
| Gross Profit | 12.35M | 16.09M | 9.89M | 14.40M | 16.35M | 20.95M | 14.23M | 19.23M | 20.75M | 26.06M | 19.54M | 24.52M | 26.18M | 32.02M | 26.26M | 31.50M | 35.37M | 41.10M | 31.07M | 24.91M | 34.97M | 41.85M | 30.23M | 36.20M | 36.97M | 33.86M | 43.22M | 46.79M | 41.47M | 48.30M | 49.36M | 43.43M | 54.10M | - | - | 45.35M | 58.79M | 65.00M | 81.01M | 57.61M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 49.89M | 54.71M | 54.04M | 62.23M | 59.15M |
| Operating Income | 1.46M | 3.25M | -1.79M | 1.79M | 974.00K | 3.29M | -2.93M | 730.00K | 1.26M | 4.93M | -1.83M | 1.31M | 1.37M | 2.14M | -1.80M | 3.05M | 3.20M | 6.05M | -4.45M | -7.96M | 1.79M | 6.99M | -4.08M | -76.00K | -1.37M | -14.90M | -4.09M | -1.62M | -3.81M | 2.06M | 7.99M | -2.96M | 5.85M | - | - | -4.54M | 4.08M | 10.96M | 18.77M | -1.53M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.92M | 6.59M | 13.27M | 21.08M | 771.00K |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 424.00K | 410.00K | 193.00K | 11.00K | 28.00K |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -4.07M | 4.52M | 11.44M | 19.45M | -896.00K |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.10M | 1.31M | 3.23M | 8.81M | 867.00K |
| Net Income | 876.00K | - | -980.00K | 988.00K | 492.00K | - | -1.50M | 3.79M | 1.34M | - | -50.00K | 2.57M | 1.75M | - | 1.47M | 2.79M | 2.43M | - | -1.31M | -13.85M | 2.42M | - | -2.27M | 1.30M | -3.35M | - | -4.64M | -2.28M | -1.89M | -100.00K | 22.30M | -2.21M | 4.30M | - | - | -2.97M | 3.22M | 8.21M | 10.63M | -1.76M |
| Diluted EPS | 0.03 | 0.06 | -0.45 | 0.04 | 0.01 | 0.13 | -0.09 | 0.20 | 0.07 | 0.12 | 0.00 | 0.13 | 0.09 | 0.12 | 0.08 | 0.14 | 0.12 | 0.22 | -0.07 | -0.72 | 0.12 | 0.61 | -0.12 | 0.07 | -0.17 | -0.78 | -0.23 | -0.11 | -0.09 | 0.00 | 0.94 | -0.09 | 0.18 | - | - | -0.13 | 0.14 | 0.36 | 0.46 | -0.08 |
| R&D Expense | 1.09M | - | 980.00K | 1.05M | 1.28M | - | 1.12M | 1.47M | 1.12M | - | 1.44M | 1.29M | 1.22M | - | 1.28M | 1.23M | 1.47M | - | 1.68M | 1.10M | 1.10M | - | 1.27M | 1.21M | 1.41M | 1.52M | 1.85M | 1.58M | 2.23M | 1.83M | 1.96M | 2.14M | 2.23M | 2.42M | - | 1.74M | 2.02M | 2.19M | - | 2.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 84.54M | 109.28M | 143.75M | 189.49M | 187.13M | 208.06M | 246.78M | 274.42M | 292.98M | 329.52M |
| Cost of Revenue | - | - | - | - | - | - | - | - | 70.81M | 79.29M | 76.30M | 79.38M |
| Gross Profit | 35.02M | 45.96M | 61.60M | 80.27M | 102.26M | 134.24M | 132.81M | 148.21M | 175.98M | 195.13M | 216.69M | 250.15M |
| Operating Expenses | - | - | - | - | - | - | - | - | 188.73M | 177.09M | 194.51M | 220.87M |
| Operating Income | 3.80M | 3.45M | 4.27M | 3.90M | 2.99M | 10.50M | -3.63M | -1.76M | -12.76M | 18.04M | 22.18M | 29.28M |
| EBITDA | - | - | - | - | - | - | - | - | 1.75M | 26.46M | 32.37M | 39.02M |
| Interest Expense | - | - | - | - | - | - | - | - | 2.79M | 4.15M | 2.08M | 1.04M |
| Pretax Income | - | - | - | - | - | - | - | - | -15.47M | 15.77M | 23.49M | 31.34M |
| Tax Provision | - | - | - | - | - | - | - | - | 2.39M | -12.74M | 6.53M | 12.25M |
| Net Income | 2.07M | 1.39M | 2.88M | 5.86M | 6.62M | 10.97M | -620.00K | -11.81M | -17.87M | 28.52M | 16.96M | 19.09M |
| Diluted EPS | 0.02 | -0.15 | 0.15 | 0.31 | 0.34 | 0.56 | -0.03 | -0.60 | -0.89 | 1.23 | 0.70 | 0.82 |
| R&D Expense | 2.84M | 4.31M | 4.48M | 5.06M | 5.29M | 5.17M | 5.26M | 5.66M | 7.09M | 7.82M | 8.83M | 8.48M |
Compounded Sales Growth
| 5 Years: | 10.12% |
| 1 Year: | 22.80% |
Compounded Profit Growth
| 5 Years: | 68.94% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +149.09% |
| 6 Months: | -5.56% |
| 3 Months: | -15.98% |
| 1 Month: | +9.38% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 36.97M | 73.94M | 88.45M | 107.07M | 151.75M | 174.09M | - | 255.00M | 281.44M | 297.92M | 273.94M |
| Current Assets | - | - | - | - | - | - | - | - | - | 119.76M | 145.29M | 177.56M | 165.17M |
| Cash & Equivalents | 6.54M | 5.42M | 7.06M | 30.70M | 23.97M | 20.10M | 22.77M | 47.85M | - | 21.93M | 61.03M | 94.37M | 83.45M |
| Inventory | - | - | - | - | - | - | - | - | - | 23.12M | 22.53M | 18.67M | 14.03M |
| Receivables | - | - | - | - | - | - | - | - | - | 54.83M | 43.17M | 44.94M | 43.88M |
| Total Liabilities | - | - | 9.70M | 14.30M | 15.66M | 17.80M | 39.16M | 49.34M | - | 133.60M | 87.80M | 81.33M | 55.04M |
| Current Liabilities | - | - | 9.50M | 13.79M | 14.52M | 16.08M | 21.43M | 26.71M | - | 64.33M | 41.06M | 40.70M | 40.96M |
| Long Term Debt | - | - | - | - | - | - | - | - | 51.79M | 45.90M | 26.18M | 23.22M | - |
| Total Debt | - | - | - | - | - | - | - | - | - | 72.23M | 50.38M | 45.11M | 15.96M |
| Total Equity | -7.11M | -6.43M | -5.65M | 59.64M | 72.79M | 89.27M | 112.59M | 124.75M | - | 121.40M | 193.64M | 216.60M | 218.90M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | 20.25M | 23.60M | 23.88M | 22.44M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.40M | 7.03M | 4.19M | 9.01M | 2.51M | 2.79M | - | 5.21M | 35.85M | 40.66M | 42.81M |
| Investing Cash Flow | - | -615.00K | -11.84M | -14.02M | -14.73M | -2.33M | 20.18M | - | -1.91M | -2.48M | -2.50M | -2.54M |
| Financing Cash Flow | - | -140.00K | 28.45M | 3.09M | 1.85M | 2.50M | 2.11M | - | -9.60M | 5.73M | -4.82M | -51.20M |
| Capital Expenditure | -353.00K | -592.00K | -775.00K | -3.75M | -4.20M | -5.45M | -2.06M | - | -1.92M | -2.48M | -2.51M | -2.54M |
| Free Cash Flow | - | 1.81M | 6.26M | 446.00K | 4.81M | -2.94M | 735.00K | - | 3.29M | 33.37M | 38.15M | 40.28M |
| Net Change in Cash | - | - | - | - | - | - | - | - | -6.30M | 39.10M | 33.33M | -10.92M |
| Share Buybacks | - | - | - | 493.00K | - | - | - | - | - | - | 3.51M | 26.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 72.9% | 73.4% | 71.1% | 70.8% | 71.0% | 71.2% | 71.3% | 71.1% | 74.0% | 75.9% |
| Operating Margin % | - | - | 5.1% | 3.6% | 2.1% | 5.5% | -1.9% | -0.8% | -5.2% | 6.6% | 7.6% | 8.9% |
| Net Margin % | - | - | 3.4% | 5.4% | 4.6% | 5.8% | -0.3% | -5.7% | -7.2% | 10.4% | 5.8% | 5.8% |
| ROE % | -32.2% | -24.7% | 4.8% | 8.0% | 7.4% | 9.7% | -0.5% | - | -14.7% | 14.7% | 7.8% | 8.7% |
| ROCE % | - | 12.6% | 7.1% | 5.3% | 3.3% | 8.1% | -2.5% | - | -6.7% | 7.5% | 8.6% | 12.6% |
Shareholding Pattern
Insiders
2.31%
Institutions
103.27%
Public Float
105.71%
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.89% | 1.78M | $43.79M |
| 2 | Morgan Stanley | 6.13% | 1.38M | $34.03M |
| 3 | Dimensional Fund Advisors LP | 4.79% | 1.08M | $26.57M |
| 4 | Cadian Capital Management, LP | 4.62% | 1.04M | $25.62M |
| 5 | Vanguard Capital Management LLC | 4.19% | 945.10K | $23.26M |
| 6 | Acadian Asset Management. LLC | 4.01% | 905.37K | $22.28M |
| 7 | Driehaus Capital Management, LLC | 3.29% | 741.91K | $18.26M |
| 8 | Vanguard Portfolio Management LLC | 2.96% | 668.33K | $16.45M |
| 9 | Federated Hermes, Inc. | 2.93% | 660.96K | $16.27M |
| 10 | Arrowstreet Capital, Limited Partnership | 2.83% | 638.37K | $15.71M |
Analyst View
Loading analyst coverage…
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TCMD
No recent headlines available.